

SPARC/Sec/SE/2021-22/64

November 01, 2021

**National Stock Exchange of India Ltd.,**  
Exchange Plaza, 5th Floor,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (East), Mumbai – 400 051.

**BSE Limited,**  
Market Operations Dept.  
P. J. Towers,  
Dalal Street,  
Mumbai - 400 001.

**Ref:** Scrip Code: NSE: SPARC; BSE: 532872

Dear Sir/ Madam,

**Sub: Outcome of the Board Meeting held today i.e. November 01, 2021**

The Board of Directors of the Company at its meeting held today i.e. November 01, 2021 has *inter alia*, considered and approved the Unaudited Financial Results for the quarter and half year ended September 30, 2021

Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), the Unaudited Financial Results of the Company, for the quarter and half year ended September 30, 2021 along with the Limited Review Report, issued by the Statutory Auditors of the Company, thereon are enclosed herewith.

The meeting of the Board of Directors of the Company commenced at 06:00 p.m. and concluded at 21:05 p.m.

This is for your information and dissemination.

For **Sun Pharma Advanced Research Company Ltd.**



**Dinesh Lahoti**  
**Company Secretary and Compliance Officer**  
**ICSI Membership No.: A22471**

Encl: As above


**Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended****Review Report to  
The Board of Directors  
Sun Pharma Advanced Research Company Limited**

1. We have reviewed the accompanying statement of unaudited financial results of Sun Pharma Advanced Research Company Limited (the "Company") for the quarter ended September 30, 2021 and year to date from April 01, 2021 to September 30, 2021 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For S R B C & CO LLP**

Chartered Accountants

ICAI Firm registration number: 324982E/E300003



per Paul Alvares

Partner

Membership No.: 105754

UDIN: 21105754AAAAIE9722

Place: Pune

Date: November 01, 2021



**Statement of Unaudited Financial Results for the Quarter and Half Year Ended September 30, 2021**

Particulars	Quarter ended			Half Year ended		Year ended
	30.09.2021	30.06.2021	30.09.2020	30.09.2021	30.09.2020	31.03.2021
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Revenue from operations	2,787	2,199	1,764	4,986	20,309	25,296
Other income	598	30	282	628	348	541
<b>Total income</b>	<b>3,385</b>	<b>2,229</b>	<b>2,046</b>	<b>5,614</b>	<b>20,657</b>	<b>25,837</b>
<b>Expenses</b>						
Cost of materials consumed	535	287	417	822	1,041	1,818
Employee benefits expense	2,394	2,552	2,283	4,946	4,683	9,158
Clinical trial expenses / products development expense	2,562	2,449	5,475	5,011	11,644	18,402
Professional charges	2,111	1,511	1,131	3,622	2,900	5,393
Finance costs	341	537	116	878	313	1,065
Depreciation and amortisation expenses	254	253	278	507	556	1,092
License and fees	95	98	9	193	792	945
Other expenses	607	679	686	1,286	1,408	3,078
<b>Total expenses</b>	<b>8,899</b>	<b>8,366</b>	<b>10,395</b>	<b>17,265</b>	<b>23,337</b>	<b>40,951</b>
<b>Loss before tax</b>	<b>(5,514)</b>	<b>(6,137)</b>	<b>(8,349)</b>	<b>(11,651)</b>	<b>(2,680)</b>	<b>(15,114)</b>
Tax expense	-	-	-	-	-	-
<b>Loss for the period</b>	<b>(5,514)</b>	<b>(6,137)</b>	<b>(8,349)</b>	<b>(11,651)</b>	<b>(2,680)</b>	<b>(15,114)</b>
<b>Other comprehensive income (OCI)</b>						
Items that will not be reclassified to profit or loss (net actuarial gain / (loss) on employee defined benefit plan)	38	38	(65)	76	(131)	153
<b>Total comprehensive loss for the period</b>	<b>(5,476)</b>	<b>(6,099)</b>	<b>(8,414)</b>	<b>(11,575)</b>	<b>(2,811)</b>	<b>(14,961)</b>
Paid-up equity share capital (Face value ₹ 1 each)	2,635	2,621	2,621	2,635	2,621	2,621
Other equity						(19,446)
Basic and Diluted loss per equity share of ₹ 1 each	(2.09)	(2.34)	(3.19)	(4.44)	(1.02)	(5.77)
	Not annualised	Not annualised	Not annualised	Not annualised	Not annualised	
<i>See accompanying notes to the financial results</i>						

**Notes :**

- The above unaudited financial results have been prepared in accordance with Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued there under and as per the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and have been taken on record by the Board of Directors at its meeting held on November 1, 2021 after being reviewed by the Audit Committee and have been subjected to a limited review by Statutory Auditors of the Company.
- The Company has only one reportable business segment namely 'Pharmaceutical Research & Development'.
- On July 08, 2021, the Company has allotted 6,24,74,082 warrants, each convertible into one equity share, on preferential basis at an issue price of ₹ 178/- each, upon receipt of 25% of the issue price (i.e. ₹ 44.50 per warrant) as warrant subscription money. Balance 75% of the issue price (i.e. ₹ 133.50 per warrant) shall be payable within 18 months from the allotment date, at the time of exercising the option to apply for fully paid-up equity share of ₹ 1/- each of the Company, against each warrant held by the warrant holder.
- The global spread of COVID-19 has been a fluid and challenging situation faced by all the industries. The Company has taken all possible effective measures to limit and keep the impact of COVID-19 under control in order to ensure business continuity with minimal disruption. The Company has considered internal and external information while finalizing various estimates in relation to its financial results upto the date of approval by the Board of Directors. The Company continues to pay close attention to the development of COVID-19, and will further evaluate and actively respond to such impact on the financial position and financial performance of the Company.
- The date of implementation of the Code on Wages 2019 and the Code on Social Security, 2020 is yet to be notified by the Government. The Company will assess the impact of these Codes and give effect in the subsequent financial results when the Rules/Schemes thereunder are notified.
- Previous period figures have been regrouped / rearranged, wherever necessary.

Mumbai, November 1, 2021



For and on behalf of the Board

*Dilip S. Shanghi*

Dilip S. Shanghi  
Chairman



**Sun Pharma Advanced Research Company Limited**

Regd. Office: Plot No. 5 & 6/1, Savli, G. I. D. C. Estate, Savli - Vadodara Highway,

Manjusar, Vadodara – 391 775. Tel. : +91-2667 666800

CIN : L73100GJ2006PLC047837. Website : www.sparc.life

**Statement of Unaudited Assets and Liabilities as at September 30, 2021**

₹ in Lakhs

Particulars	As at 30.09.2021 Unaudited	As at 31.03.2021 Audited
<b>ASSETS</b>		
<b>(A) Non-current assets</b>		
(a) Property, plant and equipment	8,900	8,987
(b) Capital work-in-progress	440	523
(c) Other intangible assets	58	69
(d) Intangible assets under development	186	-
(e) Financial assets		
(i) Other financial assets	44	40
(f) Deferred tax assets (net)	-	-
(g) Income tax assets (net)	6,040	7,024
(h) Other non-current assets	40	15
<b>Total non-current assets (A)</b>	<b>15,708</b>	<b>16,658</b>
<b>(B) Current assets</b>		
(a) Financial assets		
(i) Investments	2,473	643
(ii) Trade receivables	2,374	1,758
(iii) Cash and cash equivalents	5,825	930
(iv) Bank balances other than (iii) above	1	1
(v) Loans	10	7
(vi) Other financial assets	176	0
(b) Other current assets	3,011	2,642
<b>Total current assets (B)</b>	<b>13,870</b>	<b>5,981</b>
<b>(C) Assets held for sale</b>	-	331
<b>TOTAL ASSETS</b>	<b>29,578</b>	<b>22,970</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
(a) Equity share capital	2,635	2,621
(b) Other equity	(2,163)	(19,446)
<b>Total equity</b>	<b>472</b>	<b>(16,825)</b>
<b>Liabilities</b>		
<b>(A) Non-current liabilities</b>		
(a) Financial liabilities		
(i) Borrowings	3,750	11,250
(i.a) Lease liabilities	335	422
(b) Provisions	819	863
(c) Other non-current liabilities	3,924	3,924
<b>Total non-current liabilities (A)</b>	<b>8,828</b>	<b>16,459</b>
<b>(B) Current liabilities</b>		
(a) Financial liabilities		
(i) Borrowings	11,250	11,805
(i.a) Lease liabilities	170	162
(ii) Trade payables		
- Total outstanding dues of micro enterprises and small enterprises	72	7
- Total outstanding dues of creditors other than micro enterprises and small enterprises	6,452	9,110
(iii) Other financial liabilities	1,335	1,168
(b) Other current liabilities	459	509
(c) Provisions	540	575
<b>Total current liabilities (B)</b>	<b>20,278</b>	<b>23,336</b>
<b>Total liabilities</b>	<b>29,106</b>	<b>39,795</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>29,578</b>	<b>22,970</b>

All "0" represents amounts less than ₹ 1 Lakh.

**SIGNED FOR IDENTIFICATION**  
BY  
SRBC  
**SRBC & CO LLP**  
MUMBAI



*SRBC*

**Sun Pharma Advanced Research Company Limited**  
 Regd. Office: Plot No. 5 & 6/1, Savli, G. I. D. C. Estate, Savli - Vadodara Highway,  
 Manjusar Vadodara – 391 775. Tel. : +91-2667 666800  
 CIN : L73100GJ2006PLC047837. Website : www.sparc.life  
**Statement of Unaudited Cash Flow for the Half Year Ended September 30, 2021**

₹ In Lakhs

Particulars	Half Year ended 30.09.2021	Half Year ended 30.09.2020
	Unaudited	Unaudited
<b>A. Cash flow from operating activities</b>		
Loss before tax	(11,651)	(2,680)
<b>Adjustments to reconcile loss before tax to net cash flows:</b>		
Depreciation and amortisation expenses	507	556
Gain on disposal of property, plant and equipment (net)	(470)	(16)
Finance costs	878	313
Interest income	(128)	(39)
Net gain on sale of financial assets measured at fair value through profit or loss	(19)	(36)
Net gain arising on financial assets measured at fair value through profit or loss	(7)	(3)
Net unrealised foreign exchange loss	6	61
Products development expense	-	2,849
<b>Operating (loss) / profit before working capital changes</b>	<b>(10,884)</b>	<b>1,005</b>
<b>Working capital adjustments :</b>		
(Increase) / decrease in trade receivables	(615)	132
(Increase) / decrease in other assets	(380)	1,689
Increase / (decrease) in trade payables	(2,602)	(3,443)
Increase / (decrease) in other liabilities	221	(120)
Increase / (decrease) in provisions	(3)	(113)
<b>Cash used in operations</b>	<b>(14,263)</b>	<b>(850)</b>
Direct taxes (paid) net of refund	1,106	(725)
<b>Net cash used in operating activities (A)</b>	<b>(13,157)</b>	<b>(1,575)</b>
<b>B. Cash flow from investing activities</b>		
Payments for purchase of property, plant and equipment (including capital work-in-progress, intangible assets and intangible assets under development)	(585)	(297)
Proceeds from disposal of property, plant and equipment (net)	809	21
Purchase of investment (net)	(1,974)	(1,858)
Bank balances not considered as cash and cash equivalents		
Fixed deposits matured	-	9
Interest received	0	1
<b>Net cash used in investing activities (B)</b>	<b>(1,750)</b>	<b>(2,124)</b>
<b>C. Cash flow from financing activities</b>		
Proceeds from borrowings	6,000	12,589
Re-payment of borrowings	(14,055)	(8,445)
Payment of lease liabilities	(105)	(210)
Proceeds from issue of warrants convertible into equity shares	27,177	-
Transaction costs on issue of warrants convertible into equity shares	(804)	-
Proceeds from issue of equity shares (on conversion of warrants)	2,500	-
Interest paid	(912)	(189)
<b>Net cash generated from financing activities (C)</b>	<b>19,801</b>	<b>3,745</b>
<b>Net Increase in cash and cash equivalents (A+B+C)</b>	<b>4,894</b>	<b>46</b>
Cash and cash equivalents at the beginning of the year	930	35
Effect of exchange differences on restatement of foreign currency cash and cash equivalents	1	(1)
<b>Cash and cash equivalents at the end of the year</b>	<b>5,825</b>	<b>80</b>

All "0" represents amounts less than ₹ 1 Lakh.



**SIGNED FOR IDENTIFICATION**  
**BY**  
 SRBC  
**S R B C & CO LLP**  
**MUMBAI**